- Home
- SJT vs GLUE Comparison
SJT vs GLUE Comparison
Compare SJT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- GLUE
- Stock Information
- Founded
- SJT 1980
- GLUE 2019
- Country
- SJT United States
- GLUE United States
- Employees
- SJT N/A
- GLUE N/A
- Industry
- SJT Oil & Gas Production
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- SJT Energy
- GLUE Health Care
- Exchange
- SJT Nasdaq
- GLUE Nasdaq
- Market Cap
- SJT 281.5M
- GLUE 276.2M
- IPO Year
- SJT N/A
- GLUE 2021
- Fundamental
- Price
- SJT $6.22
- GLUE $4.87
- Analyst Decision
- SJT
- GLUE Buy
- Analyst Count
- SJT 0
- GLUE 2
- Target Price
- SJT N/A
- GLUE $13.50
- AVG Volume (30 Days)
- SJT 238.6K
- GLUE 413.8K
- Earning Date
- SJT 08-13-2025
- GLUE 08-07-2025
- Dividend Yield
- SJT N/A
- GLUE N/A
- EPS Growth
- SJT N/A
- GLUE N/A
- EPS
- SJT 0.02
- GLUE 0.08
- Revenue
- SJT $1,931,777.00
- GLUE $159,487,000.00
- Revenue This Year
- SJT N/A
- GLUE $49.02
- Revenue Next Year
- SJT N/A
- GLUE N/A
- P/E Ratio
- SJT $272.04
- GLUE $62.33
- Revenue Growth
- SJT N/A
- GLUE 14889.38
- 52 Week Low
- SJT $3.21
- GLUE $3.50
- 52 Week High
- SJT $7.22
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- SJT 50.39
- GLUE 57.86
- Support Level
- SJT $6.28
- GLUE $4.42
- Resistance Level
- SJT $6.10
- GLUE $4.85
- Average True Range (ATR)
- SJT 0.30
- GLUE 0.27
- MACD
- SJT -0.01
- GLUE -0.00
- Stochastic Oscillator
- SJT 45.45
- GLUE 67.75
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.